Webinar | November 23, 2021

Leveraging Lessons From The COVID-19 Pandemic To Accelerate The Development And Production Of Viral-Based Gene Therapies

Source: Cytiva

While there are currently over 1400 clinical cell and gene therapy programs, trial recruitment, raw material supply chains, and low-yield processes are just some of the multiple challenges facing the industry. The recent pandemic revealed that with the proper framework, a drug product can be developed, clinically tested, and produced for hundreds of millions of patients in less than a year. What lessons can we apply from this effort for AAV development and production? How can we rethink regulatory filing strategy? And why does the cell and gene therapy arena so urgently need these learnings?

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development